Quantcast

Latest TYSABRI Stories

2006-03-01 21:15:39

By Karla Gale NEW YORK (Reuters Health) - Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week's New England Journal of Medicine. "The available drugs for MS, interferon and Copaxone, have been shown in trials to reduce relapse rate by one third," Dr. Richard A. Rudick, of the Cleveland Clinic Foundation in...

2004-11-27 12:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....

2004-11-26 06:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related